Literature DB >> 16455011

Other than potency, are all statins the same?

Nicola Abate1, Manisha Chandalia.   

Abstract

Statins have been shown to interact with metabolic pathways that potentially affect physiologic functions beyond cholesterol balance. We may broadly categorize non-lipid effects of statins as clinically favorable or clinically detrimental. Whether non-lipid effects of statins are of clinical significance and whether there are differences in non-lipid effects among statins remain points of major current controversy. This review evaluates the available information on potential differences among statins in non-lipid effects.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16455011     DOI： 10.1007/s11883-006-0061-5

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  47 in total

1.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

2.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.

Authors:  G O'Driscoll; D Green; R R Taylor
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

3.  ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.

Authors:  Allen J Taylor; Steven M Kent; Patrick J Flaherty; Louis C Coyle; Thor T Markwood; Marina N Vernalis
Journal:  Circulation       Date:  2002-10-15       Impact factor: 29.690

4.  Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome.

Authors:  Feyzullah Güçlü; Bilgin Ozmen; Zeliha Hekimsoy; Cengiz Kirmaz
Journal:  Biomed Pharmacother       Date:  2004-12       Impact factor: 6.529

5.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

6.  Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study.

Authors:  Peter P Zandi; D Larry Sparks; Ara S Khachaturian; Joann Tschanz; Maria Norton; Martin Steinberg; Kathleen A Welsh-Bohmer; John C S Breitner
Journal:  Arch Gen Psychiatry       Date:  2005-02

7.  Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.

Authors:  Yang Yu; Koji Ohmori; Yan Chen; Chubun Sato; Hideyasu Kiyomoto; Kaori Shinomiya; Hiroto Takeuchi; Katsufumi Mizushige; Masakazu Kohno
Journal:  J Am Coll Cardiol       Date:  2004-08-18       Impact factor: 24.094

8.  Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.

Authors:  H A Kleinveld; P N Demacker; A F De Haan; A F Stalenhoef
Journal:  Eur J Clin Invest       Date:  1993-05       Impact factor: 4.686

9.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.